Stay updated with breaking news from Robertl gershon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is supporting research to determine if Cellvizio can be effective in severe acute and/or long COVID-19 patients suffering from lingering respiratory complications. Mauna Kea Technologies is offering in-kind funding to researchers evaluating what role Cellvizio may play in the care management of COVID-19 patients, by assessing lung fibrosis and microvascularization changes, and alveolar and capillary morphology damages; symptoms observed in severe acute and/or long COVID-19 patients with mild to severe respiratory infections. Interested clinical teams can submit their projects to this website: www.landing.maunakeatech.com/covid19. ....
Mauna Kea Technologies: Cellvizio Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification New peer-reviewed systematic meta-analysis puts Cellvizio diagnostic accuracy at 99% Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced the publication of a peer-reviewed study on pancreatic cystic lesion (PCL) risk stratification using artificial intelligence (AI) models for nCLE image classification and the publication of a new peer-reviewed meta-analysis on endoscopic ultrasound (EUS) guided nCLE for PCL evaluation. The majority of PCLs incidentally found in the population represent intraductal papillary mucinous neoplasms (IPMNs), a precursor of pancreatic adenocarcinoma. Current standard of care relies on a combination of clinical history, ....
Mauna Kea Technologies Reports Fourth Quarter and Full Year 2020 Sales Full year sales decreased 12% year-over-year; U.S. sales up 4% year-over-year 2H 20 total sales up 27% year-over-year Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced sales results for the fourth quarter and twelve months of fiscal year 2020. Fourth Quarter of 2020 Sales Summary Total sales for the fourth quarter of 2020 increased €0.7 million, or 41% year-over-year, to €2.4 million Consumables sales decreased €0.1 million, or 5% year-over-year, to €1.0 million Systems sales increased €0.7 million, or 192% year-over-year, to €1.1 million Services sales decreased 2% year-over-year to €0.3 million ....
Mauna Kea Technologies Reports Preliminary Fourth Quarter 2020 Sales U.S. Sales up 34% to 38% year-over-year and up 20% to 23% quarter-over-quarter. Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced preliminary sales for the fourth quarter of 2020. Given the significant uncertainties associated with pace of recovery from the COVID-19 pandemic, the Company has elected to provide, in this context, specific information on expected revenue trends for the fourth quarter of 2020. Preliminary sales figures for the fourth quarter of 2020 are unaudited. Preliminary Sales Summary for Fourth Quarter 2020 (Unaudited figures) ....
Regulatory News: biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, Mauna Kea ) inventor of Cellvizio, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology. The Telix and Mauna Kea scientific and clinical research collaboration is called the Imaging and Robotics in Surgery (IRiS) Alliance, or IRiS Alliance, and was created to further develop the combined technological capabilities of both companies. The IRiS Alliance was formed based on the belief that the use of cancer-specific Positron Emission Tomography (PET) imaging agents, including dual-modality tracers that combine PET and fluorescent (optical) techniques, in conjunction with confocal las ....